NTRK1-3 fusions in sarcomas: prevalence, significance, and clinical implications – a systematic review
Shahd Hamran, Zaineh Alnoubani, Aly Mostafa Hassan, Amani A Al-Rajhi, Humam Emad Rajha, Munirah Altaissan, Giridhara R Babu, Zoran Gatalica, Semir Vranić · 2025
Read NTRK1-3 fusions in sarcomas: prevalence, significance, and clinical implications – a systematic review by Shahd Hamran, Zaineh Alnoubani, Aly Mostafa Hassan, Amani A Al-Rajhi, Humam Emad Rajha, Munirah Altaissan, Giridhara R Babu, Zoran Gatalica, Semir Vranić (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12931729.txt.
Description
Some sarcomas carry gene fusions that switch on growth kinases, and drugs exist to block them. Shahd Hamran and co-authors review NTRK fusions across sarcoma research. They gathered 136 studies covering 18,077 patients. Just 551 patients tested positive, mostly for NTRK1 or NTRK3 fusions. One fusion, ETV6-NTRK3, appeared most often. Sequencing was the main detection method.
The inhibitor larotrectinib was used in 142 patients and answered in about 84 percent. Deaths and recurrences were rare in that group. A second drug, entrectinib, answered less often, near 64 percent. The authors confirm the fusions are rare but worth hunting. Finding one can change a patient's treatment entirely.
Catalog record
| CREATOR | Shahd Hamran, Zaineh Alnoubani, Aly Mostafa Hassan, Amani A Al-Rajhi, Humam Emad Rajha, Munirah Altaissan, Giridhara R Babu, Zoran Gatalica, Semir Vranić |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 43 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |